Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Rituximab 55Cyclophosphamide 45Vincristine 23fludarabine phosphate 21Cytarabine 20fludarabine 19Etoposide 19Prednisone 18Bendamustine Hydrochloride 18ibrutinib 17Methotrexate 17Doxorubicin 17Lenalidomide 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 12venetoclax 11Melphalan 11Dexamethasone 11Whole-Body Irradiation 8Tacrolimus 8Busulfan 8Brentuximab Vedotin 8Biopsy 8pembrolizumab 7duvelisib 7Nivolumab 7Mycophenolic Acid 7Gemcitabine 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × pevonedistat × Lymphoid × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡